$PTPI
Petros Pharmaceuticals, Inc. Stock $ptpi

$ptpi Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000141057824000401 Filed on April 01, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$1.389M	$5.822M	$5.822M
YoY Change	-44.84%	629.53%	-2.83%
Cost Of Revenue	$331.8K	$1.631M	$1.631M
YoY Change	-39.75%	85.09%	-28.75%
Gross Profit	$1.057M	$4.191M	$4.191M
YoY Change	-46.27%	-5135.65%	13.19%
Gross Profit Margin	76.11%	71.98%	71.98%
Selling, General & Admin	$2.711M	$9.261M	$9.261M
YoY Change	27.26%	216.76%	-24.14%
% of Gross Profit	256.53%	220.98%	220.98%
Research & Development	$1.556M	$2.409M	$2.409M
YoY Change	387.62%	1255.25%	38.43%
% of Gross Profit	147.21%	57.48%	57.48%
Depreciation & Amortization	$717.8K	$802.6K	$3.283M
YoY Change	-13.18%	-12.41%	-41.36%
% of Gross Profit	67.91%	19.15%	78.33%
Operating Expenses	$4.985M	$17.81M	$17.81M
YoY Change	52.15%	343.23%	-24.6%
Operating Profit	-$3.928M	-$13.62M	-$13.62M
YoY Change	200.03%	232.04%	-31.63%
Interest Expense	$1.766M	$2.569M	$2.569M
YoY Change	-2427.77%	-2064.95%	-2208.82%
% of Operating Profit
Other Income/Expense, Net	$1.766M	$2.885M	$2.885M
YoY Change	-2427.77%		-2468.17%
Pretax Income	-$2.163M	-$8.163M	-$8.163M
YoY Change	56.13%	92.9%	-59.26%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$2.163M	-$13.81M	-$13.81M
YoY Change	56.13%	227.25%	-31.06%
Net Earnings / Revenue	-155.72%	-237.26%	-237.26%
Basic Earnings Per Share	-$1.69		-$6.35
Diluted Earnings Per Share	-$1.69	-$6.35	-$6.35
COMMON SHARES
Basic Shares Outstanding	6.876M	2.201M	2.176M
Diluted Shares Outstanding	4.757M		2.176M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.08M	$13.34M	$13.34M
YoY Change	33.18%	41.49%	41.49%
Cash & Equivalents	$11.10M	$13.30M
Short-Term Investments
Other Short-Term Assets	$81.08K	$3.217M	$3.217M
YoY Change	13.01%	2227.26%	144.39%
Inventory	$1.557M	$1.610M	$1.610M
Prepaid Expenses
Receivables	$1.957M	$2.226M	$2.226M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$17.90M	$20.39M	$20.39M
YoY Change	28.76%	39.01%	39.01%
LONG-TERM ASSETS
Property, Plant & Equipment	$26.40K	$255.2K	$255.2K
YoY Change	-27.91%	551.45%	-35.82%
Goodwill
YoY Change
Intangibles	$8.256M	$8.972M
YoY Change	-27.7%	-26.73%
Long-Term Investments
YoY Change
Other Assets	$4.127M	$4.178M	$4.178M
YoY Change	1162.39%	1065.63%	-18.25%
Total Long-Term Assets	$12.41M	$13.41M	$13.41M
YoY Change	-25.54%	-24.49%	-24.49%
TOTAL ASSETS
Total Short-Term Assets	$17.90M	$20.39M	$20.39M
Total Long-Term Assets	$12.41M	$13.41M	$13.41M
Total Assets	$30.31M	$33.80M	$33.80M
YoY Change	-0.84%	4.24%	4.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.137M	$1.713M	$1.713M
YoY Change	15.01%	-5.16%	-5.16%
Accrued Expenses	$6.326M	$7.457M	$7.457M
YoY Change	75.29%	105.16%	105.88%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.554M	$1.157M	$1.157M
YoY Change	40.47%	6.14%	6.14%
Total Short-Term Liabilities	$11.22M	$10.77M	$10.77M
YoY Change	62.95%	52.39%	52.39%
LONG-TERM LIABILITIES
Long-Term Debt	$6.460M	$6.857M	$6.857M
YoY Change	-19.39%	-18.25%	-18.25%
Other Long-Term Liabilities	$123.0K	$3.688M	$3.688M
YoY Change	-44.98%	1303.87%	1303.86%
Total Long-Term Liabilities	$123.0K	$10.55M	$10.55M
YoY Change	-44.98%	3914.43%	21.9%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.22M	$10.77M	$10.77M
Total Long-Term Liabilities	$123.0K	$10.55M	$10.55M
Total Liabilities	$19.62M	$21.32M	$21.32M
YoY Change	29.73%	35.61%	35.61%
SHAREHOLDERS EQUITY
Retained Earnings	-$101.1M	-$98.90M
YoY Change	9.77%	9.04%
Common Stock	$688.00	$298.00
YoY Change	229.19%	43.27%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.787M	$12.48M	$12.48M
YoY Change
Total Liabilities & Shareholders Equity	$30.31M	$33.80M	$33.80M
YoY Change	-0.84%	4.24%	4.24%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$2.163M	-$13.81M	-$13.81M
YoY Change	56.13%	227.25%	-31.06%
Depreciation, Depletion And Amortization	$717.8K	$802.6K	$3.283M
YoY Change	-13.18%	-12.41%	-41.36%
Cash From Operating Activities	-$1.135M	-$2.260M	-$7.627M
YoY Change	51.64%	43.91%	-40.41%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$13.00M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.121M	-2.373M	11.54M
YoY Change	213.39%	1182.4%	-810.43%
NET CHANGE
Cash From Operating Activities	-1.135M	-2.260M	-7.627M
Cash From Investing Activities
Cash From Financing Activities	-1.121M	-2.373M	11.54M
Net Change In Cash	-2.256M	-4.633M	3.911M
YoY Change	103.97%	163.93%	-127.12%
FREE CASH FLOW
Cash From Operating Activities	-$1.135M	-$2.260M	-$7.627M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OperatingLeaseRightOfUseAsset
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001815903
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Registrant Name EntityRegistrantName	Petros Pharmaceuticals, Inc.
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	10022
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2991377
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2079387
CY2022Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OperatingLeaseRightOfUseAsset
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023Q3	ptpi	Number Of Trading Days Immediately Prior To Amortization Payment Is Due Considered For Calculating Conversion Price NumberOfTradingDaysImmediatelyPriorToAmortizationPaymentIsDueConsideredForCalculatingConversionPrice	P30D
CY2023Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023	us-gaap	Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList	http://fasb.org/us-gaap/2023#FairValueAdjustmentOfWarrants
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39752
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-1410058
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	1185 Avenue of the Americas
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	3rd Floor
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10036
CY2023	dei	City Area Code CityAreaCode	973
CY2023	dei	Local Phone Number LocalPhoneNumber	242-0005
CY2023	dei	Security12b Title Security12bTitle	Common Stock
CY2023	dei	Trading Symbol TradingSymbol	PTPI
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	3145008
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	6875814
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2022	dei	Auditor Firm AuditorFirmId	274
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2023	dei	Auditor Name AuditorName	Marcum LLP
CY2023	dei	Auditor Location AuditorLocation	East Hanover, New Jersey
CY2022	dei	Auditor Name AuditorName	EisnerAmper LLP
CY2022	dei	Auditor Location AuditorLocation	Iselin, New Jersey
CY2023Q4	us-gaap	Cash Cash	13336975
CY2022Q4	us-gaap	Cash Cash	9426264
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2226151
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2110246
CY2023Q4	us-gaap	Inventory Net InventoryNet	1610391
CY2022Q4	us-gaap	Inventory Net InventoryNet	1815113
CY2023Q4	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	1182899
CY2023Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	2033980
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	1316282
CY2023Q4	us-gaap	Assets Current AssetsCurrent	20390396
CY2022Q4	us-gaap	Assets Current AssetsCurrent	14667905
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28957
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	39177
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8971737
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	12244484
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	4178446
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	5111176
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	226259
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	358472
CY2023Q4	us-gaap	Assets Assets	33795795
CY2022Q4	us-gaap	Assets Assets	32421214
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1156550
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1089683
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1713253
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1806399
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5360077
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3634662
CY2023Q4	us-gaap	Payable Preferred Stock Redeemed PayablePreferredStockRedeemed	2047583
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	493288
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	537232
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10770751
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7067976
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	6857364
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	8388093
CY2023Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	3550000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	137657
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	262678
CY2023Q4	us-gaap	Liabilities Liabilities	21315772
CY2022Q4	us-gaap	Liabilities Liabilities	15718747
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Temporary Equity Value Excluding Additional Paid In Capital TemporaryEquityValueExcludingAdditionalPaidInCapital	1000
CY2023Q4	us-gaap	Temporary Equity Value Excluding Additional Paid In Capital TemporaryEquityValueExcludingAdditionalPaidInCapital	1000
CY2023Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	15000
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	0
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	10022
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0
CY2023Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	11271365
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	408982
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2991377
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2079387
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	298
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	208
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	110960324
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	107428652
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-98889581
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-90726393
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	12071041
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	16702467
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	33795795
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	32421214
CY2023	ptpi	Revenue From Contract With Customers Excluding Assessed Taxes RevenueFromContractWithCustomersExcludingAssessedTaxes	5822388
CY2022	ptpi	Revenue From Contract With Customers Excluding Assessed Taxes RevenueFromContractWithCustomersExcludingAssessedTaxes	5992054
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1631220
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2289418
CY2023	us-gaap	Gross Profit GrossProfit	4191168
CY2022	us-gaap	Gross Profit GrossProfit	3702636
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9261471
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12209162
CY2023	ptpi	Warrants Issuance Costs WarrantsIssuanceCosts	2855000
CY2022	ptpi	Gain Loss On Settlement With Vivus GainLossOnSettlementWithVivus	3389941
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2409094
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1740280
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3282967
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5598884
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	7460000
CY2023	us-gaap	Operating Expenses OperatingExpenses	17808532
CY2022	us-gaap	Operating Expenses OperatingExpenses	23618385
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-13617364
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-19915749
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	2590000
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	460000
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-13974000
CY2023	ptpi	Loss On Issuance Of Preferred Stock LossOnIssuanceOfPreferredStock	-11088997
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	515311
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	14194
CY2023	ptpi	Interest Expense On Promissory Notes InterestExpenseOnPromissoryNotes	536138
CY2022	ptpi	Interest Expense On Promissory Notes InterestExpenseOnPromissoryNotes	596018
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5454176
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-121824
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8163188
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20037573
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-8163188
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-20037573
CY2023	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	821456
CY2023	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	4829755
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13814399
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20037573
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.35
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.35
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-9.68
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-9.68
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2176017
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2176017
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2070210
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2070210
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	16702467
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	417230
CY2023	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	4829755
CY2023	us-gaap	Preferred Stock Redemption Discount PreferredStockRedemptionDiscount	556733
CY2023Q4	us-gaap	Preferred Stock Redemption Amount PreferredStockRedemptionAmount	1195743
CY2023	ptpi	Temporary Equity Redemption Premium TemporaryEquityRedemptionPremium	-264723
CY2023	ptpi	Reclassification Of Warrant Liability Upon Warrant Modification ReclassificationOfWarrantLiabilityUponWarrantModification	7570000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-8163188
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	12071041
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	35544964
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1195076
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-20037573
CY2022Q4	us-gaap	Shares Outstanding SharesOutstanding	16702467
CY2023	us-gaap	Profit Loss ProfitLoss	-8163188
CY2022	us-gaap	Profit Loss ProfitLoss	-20037573
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3282967
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5598884
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	7460000
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	28228
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-170816
CY2023	ptpi	Inventory And Sample Inventory Reserve InventoryAndSampleInventoryReserve	-68889
CY2022	ptpi	Inventory And Sample Inventory Reserve InventoryAndSampleInventoryReserve	-18998
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	132212
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	117085
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	2590000
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	460000
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-13974000
CY2023	ptpi	Loss On Issuance Of Series Preferred Stock LossOnIssuanceOfSeriesPreferredStock	11088997
CY2023	ptpi	Noncash Warrant Expense NoncashWarrantExpense	1595000
CY2022	ptpi	Gain Loss On Settlement With Vivus GainLossOnSettlementWithVivus	3389941
CY2023	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	417230
CY2022	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	1195076
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	144133
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-515957
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-273611
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	835317
CY2023	ptpi	Increase Decrease In Prepaid Inventories IncreaseDecreaseInPrepaidInventories	1182899
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-215032
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1648252
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-93148
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2751570
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1725415
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1802422
CY2023	ptpi	Increase Decrease Of Deferred Revenue IncreaseDecreaseOfDeferredRevenue	-164133
CY2022	ptpi	Increase Decrease Of Deferred Revenue IncreaseDecreaseOfDeferredRevenue	211029
CY2023	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	120190
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	65369
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-125021
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-142340
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7626529
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12797325
CY2023	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-1463862
CY2022	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-1623983
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	15000003
CY2023	us-gaap	Payments For Repurchase Of Preferred Stock And Preference Stock PaymentsForRepurchaseOfPreferredStockAndPreferenceStock	1998901
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11537240
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1623983
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3910711
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-14421308
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9426264
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23847572
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13336975
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9426264
CY2023	us-gaap	Interest Paid Net InterestPaidNet	536138
CY2022	us-gaap	Interest Paid Net InterestPaidNet	596018
CY2022	ptpi	Noncash Decrease In Accrued Expenses Related To Vivus Settlement NoncashDecreaseInAccruedExpensesRelatedToVivusSettlement	-6520283
CY2022	ptpi	Noncash Decrease In Accrued Inventory Purchases Related To Vivus Settlement NoncashDecreaseInAccruedInventoryPurchasesRelatedToVivusSettlement	-14203905
CY2022	ptpi	Noncash Increase In Promissory Note Related To Vivus Settlement NoncashIncreaseInPromissoryNoteRelatedToVivusSettlement	10201758
CY2022	ptpi	Non Cash Acquisition Active Pharmaceutical Ingredient Of Purchase Agreement NonCashAcquisitionActivePharmaceuticalIngredientOfPurchaseAgreement	441149
CY2022	ptpi	Noncash Decrease In Api Purchase Commitment Related To Vivus Settlement NoncashDecreaseInApiPurchaseCommitmentRelatedToVivusSettlement	5918084
CY2022	ptpi	Noncash Decrease In Other Current Assets Api Purchase Commitment NoncashDecreaseInOtherCurrentAssetsApiPurchaseCommitment	755554
CY2022	ptpi	Noncash Issuance Of Common Stock To Non Employee NoncashIssuanceOfCommonStockToNonEmployee	3
CY2023	ptpi	Noncash Initial Fair Value Of Warrant Liability Pursuant To Private Placement NoncashInitialFairValueOfWarrantLiabilityPursuantToPrivatePlacement	21544000
CY2023	ptpi	Noncash Initial Fair Value Of Derivative Liability Pursuant To Private Placement NoncashInitialFairValueOfDerivativeLiabilityPursuantToPrivatePlacement	6140000
CY2023	ptpi	Noncash Redemption Of Series Convertible Preferred Stock NoncashRedemptionOfSeriesConvertiblePreferredStock	1195743
CY2023	ptpi	Accrued Series Convertible Preferred Payments Payable AccruedSeriesConvertiblePreferredPaymentsPayable	2047583
CY2023	ptpi	Accretion Of Series Convertible Preferred Stock To Redemption Value AccretionOfSeriesConvertiblePreferredStockToRedemptionValue	4829755
CY2023	ptpi	Accrual Of Series Convertible Preferred Stock Dividends AccrualOfSeriesConvertiblePreferredStockDividends	556733
CY2023	ptpi	Reclassification Of Warrant Liability Upon Warrant Modification ReclassificationOfWarrantLiabilityUponWarrantModification	7570000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13300000
CY2023Q4	ptpi	Working Capital WorkingCapital	9600000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-98900000
CY2023	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	8000000.0
CY2023Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	15000000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of Consolidated Financial Statements in conformity with generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the Consolidated Financial Statements and reported amounts of revenue and expenses during the reporting periods. Such estimates include the adequacy of accounts receivable reserves, return reserves, inventory reserves, assessment of long-lived assets, including intangible asset impairment, and the valuation of the warrant liability and derivative liability, among others. Actual results could differ from these estimates and changes in these estimates are recorded when known.</p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments that subject the Company to concentrations of credit risk includes cash. The Company maintains cash on deposit at U.S.-based banks in amounts which, at times, may be in excess of insured limits of $250,000.</p>
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2
CY2023Q4	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	4200000
CY2022Q4	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	2300000
CY2023	ptpi	Amount Of Returns As Reduction Of Gross Revenue AmountOfReturnsAsReductionOfGrossRevenue	3400000
CY2022	ptpi	Amount Of Returns As Reduction Of Gross Revenue AmountOfReturnsAsReductionOfGrossRevenue	9400000
CY2023	us-gaap	Revenue Practical Expedient Financing Component RevenuePracticalExpedientFinancingComponent	true
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	333158
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	111476
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2022	ptpi	Shipping Costs ShippingCosts	0
CY2023	ptpi	Shipping Costs ShippingCosts	0
CY2023Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	2887317
CY2022Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	2757839
CY2023Q4	ptpi	Accounts Receivable Distribution Service Fees AccountsReceivableDistributionServiceFees	398968
CY2022Q4	ptpi	Accounts Receivable Distribution Service Fees AccountsReceivableDistributionServiceFees	339094
CY2023Q4	ptpi	Accounts Receivable Chargebacks Accruals AccountsReceivableChargebacksAccruals	2462
CY2022Q4	ptpi	Accounts Receivable Chargebacks Accruals AccountsReceivableChargebacksAccruals	1960
CY2023Q4	ptpi	Accounts Receivable Cash Discount Allowances AccountsReceivableCashDiscountAllowances	24639
CY2022Q4	ptpi	Accounts Receivable Cash Discount Allowances AccountsReceivableCashDiscountAllowances	99671
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	235097
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	206868
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	2226151
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	2110246
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1430139
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1574683
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	180252
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	240430
CY2023Q4	us-gaap	Inventory Net InventoryNet	1610391
CY2022Q4	us-gaap	Inventory Net InventoryNet	1815113
CY2023Q4	ptpi	Inventory Finished Goods Valuation Reserves InventoryFinishedGoodsValuationReserves	295411
CY2022Q4	ptpi	Inventory Finished Goods Valuation Reserves InventoryFinishedGoodsValuationReserves	364300
CY2023Q4	ptpi	Inventory Raw Materials Valuation Reserves InventoryRawMaterialsValuationReserves	0
CY2022Q4	ptpi	Inventory Raw Materials Valuation Reserves InventoryRawMaterialsValuationReserves	2872977
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	45664
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	109414
CY2023Q4	ptpi	Prepaid Food And Drug Administration Fee Current PrepaidFoodAndDrugAdministrationFeeCurrent	937652
CY2022Q4	ptpi	Prepaid Coupon Fee Current PrepaidCouponFeeCurrent	71500
CY2023Q4	ptpi	Prepaid Purchase Commitment Asset Current PrepaidPurchaseCommitmentAssetCurrent	704729
CY2022Q4	ptpi	Prepaid Purchase Commitment Asset Current PrepaidPurchaseCommitmentAssetCurrent	663984
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	234459
CY2023Q4	ptpi	Accrued Product Returns AccruedProductReturns	4178176
CY2022Q4	ptpi	Accrued Product Returns AccruedProductReturns	2311647
CY2023Q4	ptpi	Accrued Contract Rebates AccruedContractRebates	128562
CY2022Q4	ptpi	Accrued Contract Rebates AccruedContractRebates	279018
CY2023Q4	ptpi	Due To Third Party Logistic Provider DueToThirdPartyLogisticProvider	75727
CY2022Q4	ptpi	Due To Third Party Logistic Provider DueToThirdPartyLogisticProvider	155081
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	665184
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	427500
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	15000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	51620
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	297428
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	138226
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2033980
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1316282
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	25293149
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5588665
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	7460000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	12244484
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3272747
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8971737
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2800623
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1754329
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1442186
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1212871
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	996637
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	765091
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8971737
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	409796
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5360077
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3634662
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	10201758
CY2022Q1	ptpi	Security Deposit For Sub Lease Received SecurityDepositForSubLeaseReceived	14000
CY2023	ptpi	Operating Lease Expense Per Month OperatingLeaseExpensePerMonth	7000
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	179246
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	179246
CY2023	us-gaap	Sublease Income SubleaseIncome	84000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	226259
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	358472
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	125022
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	142340
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	137655
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	262677
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	262677
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	405017
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y8M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.126
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.126
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	189374
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	187739
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	155242
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	81107
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	82325
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	318674
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	55997
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	262677
CY2023Q4	ptpi	Operating Leases Future Minimum Payments Receivable Sub Lease In Next Twelve Months OperatingLeasesFutureMinimumPaymentsReceivableSubLeaseInNextTwelveMonths	56000
CY2023Q4	ptpi	Operating Leases Future Minimum Payments Receivable Sub Lease OperatingLeasesFutureMinimumPaymentsReceivableSubLease	56000
CY2022Q4	ptpi	Lessee Operating Lease Lease Not Yet Commenced Amount LesseeOperatingLeaseLeaseNotYetCommencedAmount	0
CY2023Q4	ptpi	Lessee Operating Lease Lease Not Yet Commenced Amount LesseeOperatingLeaseLeaseNotYetCommencedAmount	0
CY2023Q4	ptpi	Common Stock Potentially Issuable Upon Achievement Of Certain Milestones CommonStockPotentiallyIssuableUponAchievementOfCertainMilestones	1423209
CY2023	ptpi	Milestones Term For Achievement Of Stock Price And Market Capitalization MilestonesTermForAchievementOfStockPriceAndMarketCapitalization	P2Y
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Number Of Shares Period Increase Decrease SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease	152166
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	260000
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Number Of Shares Period Increase Decrease SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease	2500000
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2760000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	2760000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2158658
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	61567
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	33.80
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y2M23D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	5000
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	33.40
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	7500
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	32.10
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	59067
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	34.02
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M14D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	455066
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.27
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	5000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	33.40
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	509133
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.75
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y5M15D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	66000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	138600
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	14.15
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y10M24D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	5000
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	33.40
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	1
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	417230
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1195076
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	197000
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P0Y3M7D
CY2023	ptpi	Reclassification Of Warrant Liability Upon Warrant Modification ReclassificationOfWarrantLiabilityUponWarrantModification	7570000
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1004115
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	105.85
CY2021	ptpi	Class Of Warrant Or Right Remaining Contractual Term ClassOfWarrantOrRightRemainingContractualTerm	P4Y6M
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1004115
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	105.85
CY2022	ptpi	Class Of Warrant Or Right Remaining Contractual Term ClassOfWarrantOrRightRemainingContractualTerm	P3Y6M
CY2023	ptpi	Class Of Warrant Or Right Issued ClassOfWarrantOrRightIssued	7200002
CY2023	ptpi	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Issued ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued	2.25
CY2023	ptpi	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	-278
CY2023	ptpi	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Expired ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired	-16.00
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	8203839
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	14.93
CY2023	ptpi	Class Of Warrant Or Right Remaining Contractual Term ClassOfWarrantOrRightRemainingContractualTerm	P4Y3M18D
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14698491
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1103420
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18052458
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17053830
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0385
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0156
CY2023	ptpi	Effective Income Tax Rate Reconciliation Change In Fair Value Of Derivative Liability Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiabilityPercent	0.0666
CY2023	ptpi	Effective Income Tax Rate Reconciliation Revaluation Of Warrants Percent EffectiveIncomeTaxRateReconciliationRevaluationOfWarrantsPercent	0.3595
CY2023	ptpi	Effective Income Tax Rate Reconciliation Warrant Issuance Costs Percent EffectiveIncomeTaxRateReconciliationWarrantIssuanceCostsPercent	-0.0734
CY2023	ptpi	Effective Income Tax Rate Reconciliation Loss On Issuance Of Preferred Stock Percent EffectiveIncomeTaxRateReconciliationLossOnIssuanceOfPreferredStockPercent	-0.2853
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.1125
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.4374
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2398
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0090
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0142
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	221841
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	229348
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	737719
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	818127
CY2023Q4	ptpi	Deferred Tax Assets Depreciation And Amortization DeferredTaxAssetsDepreciationAndAmortization	7458252
CY2022Q4	ptpi	Deferred Tax Assets Depreciation And Amortization DeferredTaxAssetsDepreciationAndAmortization	7379214
CY2023Q4	ptpi	Deferred Tax Assets Expenses Non Currently Deductible DeferredTaxAssetsExpensesNonCurrentlyDeductible	982475
CY2022Q4	ptpi	Deferred Tax Assets Expenses Non Currently Deductible DeferredTaxAssetsExpensesNonCurrentlyDeductible	1140594
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9475773
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6013400
CY2023Q4	ptpi	Deferred Tax Assets Interest Expense Limitation DeferredTaxAssetsInterestExpenseLimitation	251023
CY2022Q4	ptpi	Deferred Tax Assets Interest Expense Limitation DeferredTaxAssetsInterestExpenseLimitation	226588
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	400813
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2882814
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8971737
CY2023Q4	us-gaap	Assets Assets	33795795
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	12244484
CY2023	ptpi	Issuance Exceeded Percentage Limit On Common Stock Issued And Outstanding IssuanceExceededPercentageLimitOnCommonStockIssuedAndOutstanding	0.05
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18100000
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	40400000
CY2023	ptpi	Percentage Of Future Utilization Of Operating Loss Carryforwards PercentageOfFutureUtilizationOfOperatingLossCarryforwards	0.80
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	17900000
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	64062
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	51276
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5822388
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1631220
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9261471
CY2023	ptpi	Warrants Issuance Costs WarrantsIssuanceCosts	2855000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2409094
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3282967
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	2590000
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-13974000
CY2023	us-gaap	Interest Income Operating InterestIncomeOperating	515311
CY2023	ptpi	Interest Expense On Promissory Notes InterestExpenseOnPromissoryNotes	536138
CY2023	ptpi	Loss On Issuance Of Preferred Stock LossOnIssuanceOfPreferredStock	-11088997
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-8163188
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5992054
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2289418
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12209162
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	3389941
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1740280
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5598884
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	7460000
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	460000
CY2022	us-gaap	Interest Income Operating InterestIncomeOperating	14194
CY2022	ptpi	Interest Expense On Promissory Notes InterestExpenseOnPromissoryNotes	596018
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-20037573
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5822388
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5992054
CY2022Q4	us-gaap	Assets Assets	32421214
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.25
CY2023Q3	ptpi	Number Of Equal Monthly Installments For Redemption Of Preferred Stock NumberOfEqualMonthlyInstallmentsForRedemptionOfPreferredStock	13
CY2023Q3	ptpi	Preferred Stock Dividends Accrued Dividend Percentage PreferredStockDividendsAccruedDividendPercentage	0.15
CY2023	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	348711
CY2023Q4	us-gaap	Embedded Derivative Liability Measurement Input EmbeddedDerivativeLiabilityMeasurementInput	0.140
CY2023Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	821456
CY2023Q4	ptpi	Temporary Equity Dividends At Stated Rate TemporaryEquityDividendsAtStatedRate	556733
CY2023	ptpi	Temporary Equity Redemption Premium TemporaryEquityRedemptionPremium	-264723
CY2023Q3	ptpi	Maximum Percentage Of Outstanding Shares Approved For Issuance In Accordance With Nasdaq Stock Market Rules MaximumPercentageOfOutstandingSharesApprovedForIssuanceInAccordanceWithNasdaqStockMarketRules	0.1999
CY2023Q3	us-gaap	Equity Ownership Percentage Excluding Consolidated Entity And Equity Method Investee EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee	0.29
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	21544000
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-13974000
CY2023	ptpi	Fair Value Measurement With Unobservable Inputs Reconciliation Reclassification Of Warrant Liability Upon Amendment FairValueMeasurementWithUnobservableInputsReconciliationReclassificationOfWarrantLiabilityUponAmendment	-7570000

Files In Submission

Name	View Source	Status
0001410578-24-000401-index-headers.html	Edgar Link	pending
0001410578-24-000401-index.html	Edgar Link	pending
0001410578-24-000401.txt	Edgar Link	pending
0001410578-24-000401-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tmb-20231231.xsd	Edgar Link	pending
tmb-20231231x10k.htm	Edgar Link	pending
tmb-20231231xex23d1.htm	Edgar Link	pending
tmb-20231231xex23d2.htm	Edgar Link	pending
tmb-20231231xex31d1.htm	Edgar Link	pending
tmb-20231231xex31d2.htm	Edgar Link	pending
tmb-20231231xex32.htm	Edgar Link	pending
tmb-20231231xex97d1.htm	Edgar Link	pending
tmb-20231231_def.xml	Edgar Link	unprocessable
tmb-20231231_lab.xml	Edgar Link	unprocessable
tmb-20231231_pre.xml	Edgar Link	unprocessable
tmb-20231231x10k_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
tmb-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PTPI
Petros Pharmaceuticals, Inc. Stock $ptpi

2024 Q1 Form 10-K Financial Statement

#000141057824000401 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTPI Petros Pharmaceuticals, Inc. Stock $ptpi

2024 Q1 Form 10-K Financial Statement

#000141057824000401 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTPI
Petros Pharmaceuticals, Inc. Stock $ptpi